RESUMEN
BACKGROUND: Pancreatic cancer is a common malignancy with poor prognosis and limited treatment. Here we aimed to investigate the role of host chromosomal instability (CIN) and tumor microbiome in the prognosis of pancreatic cancer patients. METHODS: One hundred formalin-fixed paraffin-embedded (FFPE) pancreatic cancer samples were collected. DNA extracted from FFPE samples were analyzed by low-coverage whole-genome sequencing (WGS) via a customized bioinformatics workflow named ultrasensitive chromosomal aneuploidy detector. RESULTS: Samples are tested according to the procedure of ultrasensitive chromosomal aneuploidy detector (UCAD). We excluded 2 samples with failed quality control, 1 patient lost to follow-up and 6 dead in the perioperative period. The final 91 patients were admitted for the following analyses. Thirteen (14.3%) patients with higher CIN score had worse overall survival (OS) than those with lower CIN score. The top 20 microbes in pancreatic cancer samples included 15 species of bacteria and 5 species of viruses. Patients with high human herpesvirus (HHV)-7 and HHV-5 DNA reads exhibited worse OS. Furthermore, we classified 91 patients into 3 subtypes. Patients with higher CIN score (n =13) had the worst prognosis (median OS 6.9 mon); patients with lower CIN score but with HHV-7/5 DNA load (n = 24) had worse prognosis (median OS 10.6 mon); while patients with lower CIN score and HHV-7/5 DNA negative (n = 54) had the best prognosis (median OS 21.1 mon). CONCLUSIONS: High CIN and HHV-7/5 DNA load were associated with worse survival of pancreatic cancer. The novel molecular subtypes of pancreatic cancer based on CIN and microbiome had prognostic value.
RESUMEN
Cyclic guanosine monophosphate-adenosine monophosphate adenosine synthetase (cGAS) is a DNA sensor that detects and binds to cytosolic DNA to generate cyclic GMP-AMP (cGAMP). As a second messenger, cGAMP mainly activates the adapter protein STING, which induces the production of type I interferons (IFNs) and inflammatory cytokines. Mounting evidence shows that cGAS is extensively involved in the innate immune response, senescence, and tumor immunity, thereby exhibiting a tumor-suppressive function, most of which is mediated by the STING pathway. In contrast, cGAS can also act as an oncogenic factor, mostly by increasing genomic instability through inhibitory effects on DNA repair, suggesting its utility as an antitumor target. This article reviews the roles and the underlying mechanisms of cGAS in cancer, particularly focusing on its dual roles in carcinogenesis and tumor progression, which are probably attributable to its classical and nonclassical functions, as well as approaches targeting cGAS for cancer therapy.
Asunto(s)
Interferón Tipo I , Neoplasias , Carcinogénesis/metabolismo , Citosol/metabolismo , ADN/metabolismo , Humanos , Inmunidad Innata , Interferón Tipo I/metabolismo , Nucleotidiltransferasas/genética , Nucleotidiltransferasas/metabolismoRESUMEN
AIM: To determine the potential protective role of adiponectin in intestinal ischemia reperfusion (I/R) injury. METHODS: A rat model of intestinal I/R injury was established. The serum level of adiponectin in rats with intestinal I/R injury was determined by enzyme-linked immunosorbent assay (ELISA). The serum levels of interleukin (IL)-1ß, IL-6, and tumor necrosis factor (TNF)-α were also measured by ELISA. Apoptosis of intestinal cells was detected using the terminal deoxynucleotidyl transferase dUTP nick end labeling assay. The production of malondialdehyde (MDA) and superoxide dismutase (SOD) and villous injury scores were also measured. RESULTS: Adiponectin was downregulated in the serum of rats with intestinal I/R injury compared with sham rats. No significant changes in the expression of adiponectin receptor 1 and adiponectin receptor 2 were found between sham and I/R rats. Pre-treatment with recombinant adiponectin attenuated intestinal I/R injury. The production of pro-inflammatory cytokines, including IL-6, IL-1ß, and TNF-α, in rats with intestinal I/R injury was reduced by adiponectin pre-treatment. The production of MDA was inhibited, and the release of SOD was restored by adiponectin pre-treatment in rats with intestinal I/R injury. Adiponectin pre-treatment also inhibited cell apoptosis in these rats. Treatment with the AMP-activated protein kinase (AMPK) signaling pathway inhibitor, compound C, or the heme oxygenase 1 (HO-1) inhibitor, Snpp, attenuated the protective effects of adiponectin against intestinal I/R injury. CONCLUSION: Adiponectin exhibits protective effects against intestinal I/R injury, which may involve the AMPK/HO-1 pathway.
Asunto(s)
Adiponectina/administración & dosificación , Fármacos Gastrointestinales/administración & dosificación , Mucosa Intestinal/metabolismo , Isquemia Mesentérica/complicaciones , Oclusión Vascular Mesentérica/complicaciones , Daño por Reperfusión/prevención & control , Proteínas Quinasas Activadas por AMP/metabolismo , Adiponectina/sangre , Animales , Apoptosis , Biomarcadores/sangre , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Hemo Oxigenasa (Desciclizante)/metabolismo , Mediadores de Inflamación/sangre , Interleucina-1beta/sangre , Interleucina-6/sangre , Intestinos/irrigación sanguínea , Intestinos/patología , Malondialdehído/metabolismo , Isquemia Mesentérica/sangre , Isquemia Mesentérica/patología , Oclusión Vascular Mesentérica/sangre , Oclusión Vascular Mesentérica/patología , Ratas Wistar , Proteínas Recombinantes/administración & dosificación , Daño por Reperfusión/sangre , Daño por Reperfusión/etiología , Daño por Reperfusión/patología , Transducción de Señal , Superóxido Dismutasa/metabolismo , Factores de Tiempo , Factor de Necrosis Tumoral alfa/sangreAsunto(s)
Hipófisis/anomalías , Humanos , Lactante , Imagen por Resonancia Magnética , Masculino , SíndromeRESUMEN
AIM: To evaluate the therapeutic effects of a left ventricular assist device (LVAD) on pump failure caused by acute myocardial infarction (AMI) in dogs. METHODS: The pump failure caused by AMI was established in 18 dogs, 9 of them were treated with a LVAD that could expel the autoblood from the left ventricle into the aorta and named the experimental group, and the rest of them were treated with intravenous infusion and served as the control group. The changes of arrhythmia, mortality, pulmonary capillary wedge pressure (PCWP), left ventricular end-diastolic pressure (LVEDP), peripheral artery pressure and the diameter of left ventricular chamber were observed. RESULTS: The ratio of ventricular extrasystole and the mortality resulted from ventricular fibrillation of the experimental group were lower than that of the control group. The systolic blood pressure of peripheral artery of the control group was significantly lower (< 100 mmHg) than that of the experimental group (>100 mmHg, P < 0.01). The PCWP and LVEDP of the experimental group during all the stages 45 minutes after the procedures were significantly lower than that of the control group (P < 0.01). The left ventricular end-diastolic diameter of the control group was larger than that of the experimental groups (P < 0.01). CONCLUSION: To assist circulation by expelling autoblood from left ventricle into aorta in dogs with AMI could reduce the frequency of ventricular fibrillation, improve hemodynamics, and prevent the enlargement of left ventricle. Therefore, it could play an important role in assisting the left ventricular functions.